RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen (NASDAQ:BIIB) and maintained a price target of $317.

May 29, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen and maintained a price target of $317.
The reiteration of an Outperform rating and a maintained price target of $317 by RBC Capital is a positive signal for Biogen's stock. This suggests confidence in the company's performance and potential for growth, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100